Skip to main content

Table 2 Quality of Evidence and Strength of Recommendation for Use of Intervention Based on the GRADE System [182] (Updated to August, 2011)

From: Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective

Drug Quality of Evidence Strength of Recommendation
Second-generation antihistamines (at licensed doses) High Strong (+)
First-generation antihistamines High Strong (-)
Second-generation antihistamines (at higher than licensed doses) Moderate Weak (+)
Anti-H2-antihistamines as add-on therapy Moderate Weak (+)
Oral corticosteroids (short course) Low Weak (+)
Oral corticosteroids Very low Strong (-)
Leukotriene receptor antagonists (as add-on therapy) Low Weak (+)
Anti-inflammatory agents (dapsone, sulfasalazine, hydroxychloroquine, colchicines, mycophenolate mofetil) Low-very low Weak (+)
Immunosuppressive agents   
   Cyclosporine Moderate Weak (+)*
   Methotrexate Very low Weak (+)
   Cyclophosphamide Very low Weak (+)
Biologic agents   
   Omalizumab, Moderate Weak (+)*
   IVIG Low Weak (+)
  1. (+), recommendation for medication; (-), recommendation against medication.
  2. *Although the recommendation is "weak" according to the GRADE approach, it is stronger than in other cases based on the quality of existing evidence.